Status:

UNKNOWN

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Lead Sponsor:

Samsung Medical Center

Conditions:

Metastatic Lung Non-Small Cell Carcinoma

EGFR T790M

Eligibility:

All Genders

19+ years

Brief Summary

* It is to evaluate the safety and effectiveness of a lasertinib(LECLAZA) single drug in a actual medical environment for patients 1. Primary Purpose: Progression-free survival (PFS) 2. Secondary...

Detailed Description

□ the purpose of the study The study aims to explore the safety, efficacy and resistance of test drugs in patients with local progressive or metastatic epithelial growth factor T790M mutant non-small ...

Eligibility Criteria

Inclusion

  • Prospective cohort
  • adults over the age of 19
  • Easter Cooperative Oncology Group performance 0-4
  • Patients who are eligible for or are being treated for test medication as per permit: patients with NSCLC with local progressive or metastatic EGFR T790M mutation who have previously been treated with Generation 1 or Generation 2 EGFR TKI
  • EGFR T790M mutation allows for all results identified in tumor tissue or plasma
  • Patients with brain MR within 3 months of study participation
  • Rectrospective cohort
  • adults over the age of 19
  • Patients who are already using the test drug according to the domestic authorization of the test drug

Exclusion

  • Patients who have a history of hypersensitivity to test drugs or drugs of similar chemical structure or similar family to those of test drugs
  • Pregnant women or lactating women
  • Patients participating in other interventional clinical studies

Key Trial Info

Start Date :

July 31 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2024

Estimated Enrollment :

900 Patients enrolled

Trial Details

Trial ID

NCT05377788

Start Date

July 31 2022

End Date

June 30 2024

Last Update

May 19 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Samsung Medical Center

Seoul, South Korea, 06351

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer | DecenTrialz